Novartis: FDA grants expanded use for Entresto
(CercleFinance.com) - The US Food and Drug Administration on Tuesday expanded the use of Novartis' Entresto for the treatment of chronic heart failure.
The Swiss drugmaker said that the FDA has approved Entresto to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.
The US health regulator also noted that the drug's benefits are clearest in patients with left ventricular ejection fraction (LVEF) that is below normal.
The FDA's decision hence provides a treatment to patients who were not eligible for previous treatment because of their ejection fraction.
Approximately 6 million Americans are living with chronic heart failure, of which 2 million have below normal LVEF.
Novartis also announced on Wednesday that it has entered into an agreement with the Bill & Melinda Gates Foundation, providing funding for the discovery of a gene therapy to cure sickle cell disease, a complex genetic disorder that affects hemoglobin functions.
Copyright (c) 2021 CercleFinance.com. All rights reserved.